Clinical Trial Update: Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating GC4711 with SBRT for centrally located or large non-small cell lung cancer was terminated, with results posted on 2024-04-03.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GC4711

Snippet

Sponsor: Galera Therapeutics, Inc. | Conditions: SBRT, NSCLC | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-04-03